Peter Stärkel
About
In The Last Decade
Peter Stärkel
148 papers receiving 6.7k citations
Hit Papers
Peers
Comparison fields: 5 of 123
- Molecular Biology 3.3k
- Epidemiology 3.1k
- Pathology and Forensic Medicine 1.8k
- Hepatology 1.4k
- Physiology 1.3k
Countries citing papers authored by Peter Stärkel
This map shows the geographic impact of Peter Stärkel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Stärkel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Stärkel more than expected).
Fields of papers citing papers by Peter Stärkel
This network shows the impact of papers produced by Peter Stärkel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Stärkel. The network helps show where Peter Stärkel may publish in the future.
Co-authorship network of co-authors of Peter Stärkel
This figure shows the co-authorship network connecting the top 25 collaborators of Peter Stärkel. A scholar is included among the top collaborators of Peter Stärkel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Stärkel. Peter Stärkel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 1 | |
| 3 | 4 | |
| 4 | 0 | |
| 5 | 7 | |
| 6 | 18 | |
| 7 | 16 | |
| 8 | 6 | |
| 9 | 2 | |
| 10 | 3 | |
| 11 | 131 | |
| 12 | 16 | |
| 13 | 4 | |
| 14 | 120 | |
| 15 | Sofosbuvir in combination with simeprevir +/- ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: a real-life experience from Belgium | 3 |
| 16 | Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity breakdown → | 711 |
| 17 | Hepatitis C epidemiology in Belgium. | 5 |
| 18 | The disease burden of hepatitis C in Belgium: development of a realistic disease control strategy. | 4 |
| 19 | IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use? | 1 |
| 20 | Peg-ifn-alfa 2b With Ribavirin for the Treatment of Mild-moderate Recurrent Hepatitis C After Liver Transplantation (lt) : Impact On Fibrosis Progression. a Multicenter Randomized Controlled Study | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.